Live Analyst Rating Changes 1511 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Joseph Schwartz
LP
Joseph Schwartz
Leerink Partners
Wall Street Analyst
★★☆☆☆
#2073
on 13Foresight · ranked by our own returns
46%
Success Rate
+6.1%
Average Return
24 of 52 calls profitable · -5.2% vs benchmark
📈 Across the calls we could measure, roughly 46% of Joseph Schwartz's ratings turned a profit when each position was held for 1 year — averaging +6.1% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

94 Buy 31 Hold 0 Sell
Joseph's Stock Coverage 51 ratings · 2026-06-18
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
QURE
uniQure
 Jun 17, 2026 BUY Strong Buy
+2.0% avg upside
29 analysts
$70.00
48.50% Upside
 ·
EWTX
Edgewise Therapeutics
 Jun 16, 2026 BUY Strong Buy
+27.2% avg upside
14 analysts
$52.00
43.90% Upside
 +0.0%
CRNX
Crinetics Pharmaceuticals
 Jun 11, 2026 BUY Strong Buy
+122.6% avg upside
20 analysts
$95.00
167.79% Upside
 ·
FULC
Fulcrum Therapeutics
 Jun 02, 2026 HOLD Hold
+151.5% avg upside
13 analysts
$4.00
14.32% Upside
 ·
ASND
Ascendis Pharma
 Jun 02, 2026 BUY Strong Buy
+16.5% avg upside
24 analysts
$305.00
30.76% Upside
 +3.1%
BMRN
BioMarin Pharmaceutical
 May 18, 2026 HOLD Strong Buy
+71.7% avg upside
52 analysts
$62.00
12.97% Upside
 +10.8%
ANTX
AN2 Therapeutics, Inc.
 May 15, 2026 BUY Buy
+77.6% avg upside
7 analysts
$9.00
81.71% Upside
 +0.0%
RNA
Atrium Therapeutics, Inc.
 May 15, 2026 BUY Strong Buy
+174.3% avg upside
4 analysts
$25.00
99.59% Upside
 -4.3%
SPRB
Spruce Biosciences
 May 15, 2026 BUY Strong Buy
+98.5% avg upside
14 analysts
$120.00
133.98% Upside
 -8.3%
TSE:MSCL
Satellos Bioscience
 Apr 06, 2026 BUY Strong Buy
+280.6% avg upside
6 analysts
$28.19
245.14% Upside
 ·
WVE
Wave Life Sciences
 Mar 26, 2026 BUY Strong Buy
+272.2% avg upside
28 analysts
$25.00
310.60% Upside
 -6.2%
SRPT
Sarepta Therapeutics
 Mar 25, 2026 HOLD Buy
+251.8% avg upside
49 analysts
$15.00
13.45% Downside
 -33.7%
MAZE
Maze Therapeutics, Inc.
 Mar 25, 2026 BUY Strong Buy
+152.2% avg upside
12 analysts
$50.00
98.50% Upside
 -21.7%
GOSS
Gossamer Bio
 Feb 23, 2026 HOLD Buy
+4259.1% avg upside
17 analysts
$6.00
3477.72% Upside
 -19.1%
TVTX
Travere Therapeutics
 Jan 13, 2026 BUY Strong Buy
-14.7% avg upside
22 analysts
 — +78.8%
PHVS
Pharvaris
 Jan 13, 2026 BUY Strong Buy
+36.1% avg upside
14 analysts
$38.00
16.48% Upside
 +28.5%
RARE
Ultragenyx Pharmaceutical
 Jan 13, 2026 BUY Strong Buy
+144.1% avg upside
36 analysts
 — -4.2%
IFRX
InflaRx
 Dec 31, 2025 HOLD Buy
+391.6% avg upside
11 analysts
 — +135.6%
MREO
Mereo Biopharma Group Plc
 Dec 29, 2025 BUY Strong Buy
+1137.8% avg upside
11 analysts
$2.00
532.35% Upside
 -14.3%
SLDB
Solid Biosciences
 Dec 15, 2025 BUY Strong Buy
+112.8% avg upside
23 analysts
$20.00
162.89% Upside
 +21.2%
AUPH
Aurinia Pharmaceuticals
 Dec 03, 2025 HOLD Strong Buy
-6.0% avg upside
12 analysts
$16.00
2.03% Downside
 +10.4%
DSGN
Design Therapeutics
 Dec 03, 2025 BUY Strong Buy
+47.9% avg upside
9 analysts
$14.00
15.70% Upside
 +47.1%
MNPR
Monopar Therapeutics Inc
 Nov 10, 2025 BUY Strong Buy
+51.9% avg upside
18 analysts
$115.00
74.54% Upside
 -28.7%
PTCT
PTC Therapeutics
 Oct 16, 2025 HOLD Strong Buy
-1.0% avg upside
29 analysts
$54.00
31.27% Downside
 +17.5%
INSM
Insmed
 Sep 29, 2025 BUY Strong Buy
+80.3% avg upside
36 analysts
 — -30.5%
LRMR
Larimar Therapeutics
 Aug 15, 2025 BUY Strong Buy
+421.7% avg upside
21 analysts
$25.00
612.28% Upside
 -15.2%
PEPG
PepGen Inc.
 Aug 07, 2025 BUY Strong Buy
+506.8% avg upside
8 analysts
$10.00
474.68% Upside
 +30.2%
PSC
Principal U.S. Small-Cap Multi-Factor ETF
 Nov 08, 2024 BUY Strong Buy
1 analyst
 — +2.2%
SYBX
Synlogic
 Aug 12, 2024 HOLD Buy
+3290.3% avg upside
11 analysts
$1.00
40.82% Upside
 +4.3%
OKUR
OnKure Therapeutics
 May 07, 2024 HOLD Buy
+453.1% avg upside
12 analysts
$10.00
134.15% Upside
 -87.6%
CRL
Charles River Labs
 Sep 07, 2023 HOLD Strong Buy
+13.1% avg upside
34 analysts
$14.00
92.21% Downside
 -8.0%
RNAC
Cartesian Therapeutics
 Aug 18, 2023 HOLD Strong Buy
+221.8% avg upside
19 analysts
$30.00
211.25% Upside
 -58.1%
IONS
Ionis Pharmaceuticals
 Feb 03, 2023 HOLD Strong Buy
+13.0% avg upside
43 analysts
$34.00
54.24% Downside
 +21.6%
PTGX
Protagonist Therapeutics
 Aug 05, 2022 BUY Strong Buy
-21.5% avg upside
19 analysts
$30.00
73.46% Downside
 +67.4%
AMGN
Amgen
 Aug 04, 2022 HOLD Buy
-12.2% avg upside
57 analysts
 — +1.8%
XERS
Xeris Pharmaceuticals
 Jul 13, 2022 BUY Strong Buy
+33.3% avg upside
10 analysts
 — +67.1%
ELVN
Enliven Therapeutics
 Apr 05, 2022 HOLD Strong Buy
+7.6% avg upside
14 analysts
$4.00
91.10% Downside
 +5.8%
JPM
JPMorgan Chase
 May 07, 2021 SELL Strong Buy
-23.4% avg upside
46 analysts
 — +21.3%
TSE:WCN
Waste Connections
 Apr 15, 2021 BUY Strong Buy
+11.2% avg upside
35 analysts
$53.57
75.36% Downside
 ·
TPST
Tempest Therapeutics
 Jan 06, 2021 HOLD Buy
+1646.8% avg upside
18 analysts
$30.00
2339.04% Upside
 -80.8%
NTLA
Intellia Therapeutics
 Nov 28, 2018 BUY Buy
+158.2% avg upside
37 analysts
$23.00
49.44% Upside
 -0.5%
PRQR
ProQR
 Sep 26, 2017 BUY Strong Buy
+572.0% avg upside
18 analysts
$12.00
552.25% Upside
 +259.6%
UTHR
United Therapeutics
 Apr 03, 2017 HOLD Buy
-20.4% avg upside
26 analysts
$126.00
76.63% Downside
 -6.6%
DBVT
DBV Technologies SA - American
 Nov 13, 2016 BUY Strong Buy
+49.4% avg upside
15 analysts
 — -39.7%
MCRB
Seres Therapeutics
 Nov 10, 2016 BUY Buy
+169.8% avg upside
10 analysts
$14.00
125.72% Upside
 -20.4%
CYTOF
Altamira Therapeutics
 Nov 10, 2016 BUY Strong Buy
+21133.5% avg upside
4 analysts
$8.00
7988.89% Upside
 ·
PDSB
PDS Biotechnology
 Mar 08, 2016 BUY Strong Buy
+1583.2% avg upside
11 analysts
$24.00
2599.89% Upside
 -4.4%
REGN
Regeneron
 Oct 26, 2015 BUY Strong Buy
+27.5% avg upside
57 analysts
$664.00
10.66% Upside
 -33.5%
BIIB
Biogen
 Sep 15, 2015 BUY Strong Buy
+24.4% avg upside
51 analysts
$425.00
119.76% Upside
 -5.3%
CYTK
Cytokinetics
 May 19, 2014 BUY Strong Buy
+9.9% avg upside
36 analysts
$8.00
89.71% Downside
 +31.9%
AMRN
Amarin
 Oct 30, 2013 HOLD Buy
-47.2% avg upside
18 analysts
 — ·
🔒 46 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Joseph Schwartz — Frequently Asked Questions
How accurate are Joseph Schwartz's stock ratings?
Based on the calls 13Foresight could measure, about 46% of Joseph's ratings were profitable over a one-year hold, with an average return of +6.1% per rating, or -5.2% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Joseph ranked on 13Foresight?
Joseph Schwartz is currently ranked #2073 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Joseph cover?
Joseph most recently has ratings on QURE, EWTX, CRNX, FULC, ASND, BMRN, ANTX, RNA, SPRB, TSE:MSCL, WVE, SRPT and 39 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.